Treating HER2-low Breast Cancer With Novel Antibody Drug Conjugates

By Sandra M. Swain, MD
Zahi Mitri, MD, MS

Experts take a look at clinical data behind novel antibody drug conjugates and consider how they may impact the management of HER2-low breast cancer.

Related Videos
View All
Related Content

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

A Wealth of Clinical Trials Expands Potential Breast Cancer Treatment Options

January 26th 2023

Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer

January 16th 2023

Updates From 2022 SABCS Underscore the Continued Expansion of Treatment Options in Metastatic Breast Cancer

January 18th 2023

FDA Grants Fast Track Designation to CFI-402257 for ER+/HER2– Breast Cancer

January 11th 2023

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

A Wealth of Clinical Trials Expands Potential Breast Cancer Treatment Options

January 26th 2023

Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer

January 16th 2023

Updates From 2022 SABCS Underscore the Continued Expansion of Treatment Options in Metastatic Breast Cancer

January 18th 2023

FDA Grants Fast Track Designation to CFI-402257 for ER+/HER2– Breast Cancer

January 11th 2023

FDA Approves Elacestrant for ER+/HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer

January 27th 2023

Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer

January 23rd 2023

A Wealth of Clinical Trials Expands Potential Breast Cancer Treatment Options

January 26th 2023

Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer

January 16th 2023

Updates From 2022 SABCS Underscore the Continued Expansion of Treatment Options in Metastatic Breast Cancer

January 18th 2023

FDA Grants Fast Track Designation to CFI-402257 for ER+/HER2– Breast Cancer

January 11th 2023
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact